Home › Uterine Cancer › Oklahoma › Oklahoma City
Uterine Cancer clinical trials in Oklahoma City, OK
3 studies for Uterine Cancer are looking for participants at sites in and around Oklahoma City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
- Research Site, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
- University of Oklahoma - Health Sciences Center, Oklahoma City
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
RecruitingPhase 1
- University of Oklahoma, Oklahoma City
About Uterine Cancer
Uterine cancer is a cancer that forms in tissues of the uterus. It is more likely to happen after menopause. There are things you can do that may help lower your risk.
More about Uterine Cancer on MedlinePlus
Uterine Cancer trials in other cities
- Houston, TX8 studies
- Columbus, OH6 studies
- New York City, NY6 studies
- Boston, MA5 studies
- Philadelphia, PA5 studies
- Miami, FL5 studies
- Austin, TX5 studies
- Chicago, IL4 studies
- West Palm Beach, FL4 studies
- Providence, RI4 studies
- Orlando, FL4 studies
- Pittsburgh, PA4 studies
Other studies in Oklahoma City
- Non-Small Cell Lung Cancer28 studies
- Ovarian Cancer28 studies
- Endometrial Cancer25 studies
- Colorectal Cancer22 studies
- Prostate Cancer21 studies
- Lung Cancer19 studies
- Breast Cancer17 studies
- Metastatic Cancer16 studies
- Cancer (all types)14 studies
- Acute Myeloid Leukemia14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Bladder Cancer11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.